Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis Improvements across all patient reported outcomes (PROs) were observed from baseline to Week 8 in all PRO instruments utilized in the ABTECT ...
VICAT - CHIFFRE D'AFFAIRES T3 2025 Chiffre d’affaires en croissance au 3ème trimestre : +4,9% en organique et +1,4% en base publiéeStabilisation de l’activité ciment en France et poursuite de la reprise en SuisseBonne dynamique des pays émergents, notamment en zone Méditerranée et au BrésilEffet de change défavorable au 3ème trimestrePerspectives 2025 de chiffre d’affaires et d’EBITDA confirmées Chiffre d’affaires consolidé 9 mois 2025 : (en millions d’euros) 30 septembre2025 30 septembre 2024VariationpubliéeVariationà pcc*France897879+2,0%-4,1%Europe (hors France)336307+9,4%+7,4%Amériques...
Vicat - Q3 2025 Trading update Third quarter sales: +4.9% organic growth and +1.4% reported growthStabilization of cement activity in France and continued recovery in SwitzerlandStrong momentum in emerging countries, in the Mediterranean region and BrazilUnfavorable currency effect in the third quarter 2025 revenue and EBITDA outlook confirmed 9 months 2025 consolidated sales: (in millions of euros) September 302025 September 30 2024ChangereportedChange lfl*France897879+2.0%-4.1%Europe (excluding France)336307+9.4%+7.4%Americas711756-5.9%-1.5%Asia301345-12.9%-5.5%Mediterranean369343+7.7%+3...
A director at Abivax sold 1,200,000 shares at 94.085EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Seit August hält der aktivistische Investor Active Ownership ca. 10% der Aktien. „Im Einvernehmen mit dem Aufsichtsrat“ legt CEO D. Siemssen sein Amt zum 31.10.25 nieder. Das Vertrauen der Investoren, das auch durch die noch laufende BaFin-Bilanzprüfung litt, war aufgebraucht. Schuldenreduktion und eine neue Equity-Story stehen u.E. im Zentrum. Selektive Investitionsplanung und Kostensenkung dürften bis auf Weiteres operativ höchste Priorität behalten (Verkauf des Behälterglas-Geschäfts). Mit ...
Since August, the activist investor Active Ownership has held about 10% of the shares. “In agreement with the Supervisory Board,” CEO D. Siemssen will step down on 31.10.25. Investor confidence, which had also suffered due to the ongoing BaFin audit, had been exhausted. In our view, debt reduction and a new equity story are central. Selective investment planning and cost reduction are likely to remain the highest operational priority for the time being (sale of the container glass business).Wi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.